pegsunercept
Recombinant proteinexperimental
Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010, Phase II clinical trials have been completed. It is being developed by Amgen. — Wikipedia
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2001 (NCT00037700)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- TNF-alphaINHIBITOR
TNF inhibitor
- Tumor necrosis factor receptor R1INHIBITOR
TNFRSF1A inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPegsunercept ↗
- ChEMBLCHEMBL1743057 ↗
Also known as
- peg stnf-r1
- peg stnfri
- pegsunercept
- pegsunercept
- pegsunercept
- pegylated soluble tumor necrosis factor receptor i
- stnf-ri
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00111423 | Phase 2 | Aug 1, 2002 | Amgen |
| NCT00537667 | Phase 2 | Aug 1, 2001 | Amgen |
| NCT00037700 | Phase 2 | May 1, 2001 | Amgen |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 3 | 3 | 1 | 2001 |
1 organizations
Page 1 / 1